Skip to main content
    L

    Larimar Therapeutics Inc (LRMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.00
    -0.02 (-0.66%)

    Market Cap: $313.73M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Larimar Therapeutics Inc (LRMR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Larimar Therapeutics are Arcturus Therapeutics Holdings (ARCT), Rocket Pharmaceuticals (RCKT) and Protara Therapeutics (TARA). By market cap, Larimar Therapeutics ranks 4th of the 13 companies on this page; Gyre Therapeutics (GYRE) is the largest at $471.74M.

    Peer Comparison

    LRMR's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Larimar Therapeutics (LRMR)$313.73MN/AN/A0.0%N/A0.0%0.00%
    Arcturus Therapeutics Holdings Inc (ARCT)$240.96MN/A7.7x-285.9%N/A6.7%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Galectin Therapeutics Inc (GALT)$307.59MN/AN/A0.0%671.1%0.0%0.00%
    Avalo Therapeutics Inc (AVTX)$448.71MN/AN/A0.0%N/A-69.3%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Protalix Biotherapeutics Inc (PLX)$257.17M12.1x2.9x24.3%N/A22.8%0.00%
    Rezolute Inc (RZLT)$353.54MN/AN/A0.0%N/A0.0%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Peer median$266.25M12.1x5.8x0.0%-2.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Larimar Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Arcturus Therapeutics Holdings Inc (ARCT)
    Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases.
    ARCT competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Galectin Therapeutics Inc (GALT)
    Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic...
    GALT competitors
    Avalo Therapeutics Inc (AVTX)
    Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved...
    AVTX competitors
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Protalix Biotherapeutics Inc (PLX)
    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its...
    PLX competitors
    Rezolute Inc (RZLT)
    Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States.
    RZLT competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors

    Frequently Asked Questions About LRMR

    Who are Larimar Therapeutics' main competitors?

    The companies most similar to Larimar Therapeutics include Arcturus Therapeutics Holdings (ARCT), Rocket Pharmaceuticals (RCKT), Protara Therapeutics (TARA), Prelude Therapeutics (PRLD) and Galectin Therapeutics (GALT), listed from the closest match.

    Who is Larimar Therapeutics' biggest competitor?

    Gyre Therapeutics (GYRE) is the largest of the similar companies at $471.74M; Arcturus Therapeutics Holdings (ARCT) is the closest match by business profile, size, sector and industry.

    How does LRMR stock compare with its competitors?

    LRMR's net margin is 0.0% against a peer median of 0.0%.

    Which of Larimar Therapeutics' competitors pays a higher dividend?

    Larimar Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Larimar Therapeutics bigger than its competitors?

    No. Larimar Therapeutics is 4th by market cap among the 13 companies on this page; the largest is Gyre Therapeutics (GYRE) at $471.74M.